Reports Q2 revenue $25.12M, consensus $19.99M. “We are encouraged by the initial CX-904 Phase 1a data we shared in the second quarter that demonstrated single agent anti-cancer activity and a favorable therapeutic window for the high potential and previously undruggable target combination of EGFR and CD3, underscoring the potential of our PROBODY therapeutic platform,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- CTMX Earnings this Week: How Will it Perform?
- CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- CytomX Therapeutics Appoints Chris Ogden as New CFO
- CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer